8-K - Palvella Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation on Phase 3 SELVA Study of QTORIN™ dated February 24, 2026* 1

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

CORPORATE PRESENTATION ON PHASE 3 SELVA STUDY OF QTORIN DATED FEBRUARY 24, 2026